Univest Financial Corporation Announces Completion of $50.0 Million Subordinated Debt Offering

(NASDAQ:UVSP), SOUDERTON, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) — Univest Financial Corporation (the “Corporation”) (NASDAQ: UVSP), parent company of Univest Bank and Trust Co. and its insurance, investments and equipment financing subsidiaries, today announced the closing of a $50.0 million private placement of fixed-to-floating rate subordinated notes. The Corporation plans to use the proceeds to […]

Globus Medical Reports Third Quarter 2025 Results

(NYSE:GMED), AUDUBON, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2025. Worldwide net sales were $769.0 million, an increase of 22.9%, or an increase of 22.3% on a constant currency basis Base business, excluding Nevro,

Palomar Holdings, Inc. Reports Third Quarter 2025 Results

(NASDAQ:PLMR), LA JOLLA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) — Palomar Holdings, Inc. (NASDAQ:PLMR) (“Palomar” or “Company”) reported net income of $51.5 million, or $1.87 per diluted share, for the third quarter of 2025 compared to net income of $30.5 million, or $1.15 per diluted share, for the third quarter of 2024. Adjusted net income(1)

Rackspace Technology Reports Third Quarter 2025 Results

(NASDAQ:RXT), Revenue of $671 million in the Third Quarter, down 1% Year-over-Year Private Cloud Revenue was $250 million, down 3% Year-over-Year Public Cloud Revenue was $422 million, up 1% Year-over-Year Third Quarter 2025 Cash Flow From Operating Activities was $71 million; Cash Flow From Operating Activities was $146 million on a Trailing-Twelve-Month Basis SAN ANTONIO,

HCI Group Reports Third Quarter 2025 Results

(NYSE:HCI), TAMPA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) — HCI Group, Inc. (NYSE:HCI), reported pre-tax income of $90.6 million and net income of $67.9 million for the third quarter of 2025 compared with pre-tax income of $14.1 million and net income of $9.4 million for the third quarter of 2024. Net income after noncontrolling interests

Microchip Technology Announces Financial Results for Second Quarter of Fiscal Year 2026

(NASDAQ:MCHP), Net sales of $1.140 billion, increased 6.0% sequentially and declined 2.0% from the year ago quarter. The midpoint of our guidance provided on August 7, 2025 was net sales of $1.130 billion. On a GAAP basis: gross profit of 55.9%; operating income of $88.9 million and 7.8% of net sales; net income attributable to

Alta Equipment Group Announces Third Quarter 2025 Financial Results

(NYSE:ALTG), Third Quarter Financial Highlights: Total revenues decreased $26.2 million year over year to $422.6 million Material Handling revenues decreased $1.0 million year over year to $167.9 million, while Construction Equipment and Master Distribution revenues decreased a combined $23.9 million year over year to $256.6 million Product support revenues increased 1.1% year over year to

SRx Health Solutions Provides Response Related to Unusual Market Trading Activity Received by the NYSE American Exchange

SRx Health Solutions Provides Response Related to Unusual Market Trading Activity Received by the NYSE American Exchange GlobeNewswire November 06, 2025 TAMPA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) — SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”) today announced the Company has been notified by the NYSE American of unusual trading activity of its

Scripps reports Q3 2025 financial results

Scripps reports Q3 2025 financial results GlobeNewswire November 06, 2025 CINCINNATI, Nov. 06, 2025 (GLOBE NEWSWIRE) — The E.W. Scripps Company (NASDAQ: SSP) delivered $526 million in revenue for the third quarter of 2025. Loss attributable to the shareholders of Scripps was $49 million or 55 cents per share. Business notes: Local Media division core

Certara Reports Third Quarter 2025 Financial Results

(NASDAQ:CERT), RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025. Third Quarter Highlights: Revenue was $104.6 million, compared to $94.8 million in the third quarter of 2024, representing growth of 10%. Software

Scroll to Top